JP Morgan 2022: The Promise of Synthetic Biology
The healthcare industry kicks off each new year not when the ball drops in Times Square but with the start...
Ginkgo Bioworks Incorporates the Onyx® platform into its foundries
Ginkgo Bioworks, the leading horizontal platform for cell programming, has recently adopted the Onyx platform into its foundries. The company...
What Makes CRISPR Like a Movie Star? SynBioBeta podcast with Nandini Krishnamurthy
Nandini Krishnamurthy, Inscripta’s VP of Microbial Business, appeared as a guest on SynBioBeta’s Built with Biology podcast. The new podcast...
Inscripta Named Colorado Company of The Year
The Rockies and the Flatirons have provided beautiful and inspiring backdrops at our Boulder base, and the Colorado spirit of...
Inscripta’s MAD7™ CRISPR Nucleases Helping Hudson River Biosciences Improve Plant Editing
The rapid growth of the world’s population is posing quite a challenge for the food supply. Current projections indicate that...
New Market Report Finds Near-Boundless Opportunity in Synthetic Biology
A new U.S. thematic market report* titled “Mission Possible: How Synbio Can Drive Sustainability & Disrupt Manufacturing” from Barclays’ Equity...
Inside Inscripta: Reem Baraka, Sequencing
While Inscripta is a genome engineering company, we also make heavy use of DNA sequencing — so much that we...
Recap of SynBioBeta’s Chemicals & Materials Digital Conference
As we excitedly await the January 2022 in-person SynBioBeta Conference, the synbio community organizers are keeping the conversation alive online....
Webinar: Hypothesis-Driven and Empirical Approaches to Engineering Biology
In a recent webinar organized by the Global Institute for Food Security (GIFS), Patrick Westfall, Senior Director of Cell Biology...